ArticleClinical case reports2021
Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.
Article in Clinical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Viral reactivations and co-infections in COVID-19 patients: a systematic review.BMC infectious diseases · 2023Pooled it
- Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Pooled it
- COVID-19: gastrointestinal and hepatobiliary manifestations.Human pathology · 2023Review
- Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection.Open forum infectious diseases · 2022Article
- First case of concomitant cytomegalovirus (CMV) viremia in non-immunocompromised COVID-19 patient and ICU management strategy in Qatar with literature review.Clinical case reports · 2022Article
- Characteristics and clinical outcomes of COVID-19 patients with pulmonary disorders: A single-center, retrospective observational study.Health science reports · 2022Article
- Cytomegalovirus pneumonitis amid COVID-19 chaos: the hidden enemy-a case report.Journal of medical case reports · 2022Article
- Cytomegalovirus gastritis in a patient with severe acute respiratory syndrome coronavirus 2 infection: A case report and literature review.Respiratory medicine case reports · 2022Article
- Coronavirus Disease 2019 and Kidney Transplantation in Saudi Arabia: Outcomes and Future Opportunities.Annals of transplantation · 2021Observational
- Article
- Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.Clinical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.